Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

Casacó, Á.; López, Gerardo; García, Iván; Arsenio Rodríguez, José; Fernández, Ramsés; Figueredo, Javier; Torres, Leonel; Perera Pintado, Alejandro; F. Batista, Juan; Leyva, René; Peña, Yamilé; Amador, Zaida; González, Addys; Estupiñán, Bárbara; Coca, Marcos; Hernández, Abel; Puig, Miguel; Iglesias, Marbelia; Hernández, Astrid; Ramos, Mayra; Rodriquez, Leyanis; Alcaide Suárez, N

doi:10.4161/cbt.7.3.5414

Public

Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

Published in Cancer Biology & Therapy • Mar 1, 2008

Authors:

Á. Casacó

Gerardo López

Iván García

Abstract

Radioimmunotherapy (RIT) may improve the management of malignant gliomas. A Phase I clinical trial was performed to evaluate, for the first time, the toxicity and clinical effect of an intracavitary administration of a single dose of Nimotuzumab (h-R3) labeled wit (188)Re. Nimotuzumab is a humanized...

Subject

Nimotuzumab

Medicine

Anaplastic astrocytoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!